Graduate Program in Genetics and Molecular Biology Department of Genetics Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Department of Obstetrics and Neonatology Hospital e Maternidade SEPACO, São Paulo, Brazil.
J Pregnancy. 2024 Jun 6;2024:8915166. doi: 10.1155/2024/8915166. eCollection 2024.
There is limited evidence about the use of medications among pregnant women with COVID-19, as well as risk factors for hospitalization due to COVID-19 in pregnancy. We aimed to describe the use of medications among SARS-CoV-2-positive pregnant women at the time around infection and identify predictors for hospitalization due to COVID-19 in two hospitals in Brazil. This is a hospital record-based study among pregnant women with positive SARS-CoV-2 tests between March 2020 and August 2022 from two Brazilian hospitals. Characteristics of sociodemographic, obstetrical, and COVID-19 symptoms were extracted retrospectively. The prevalence use of medications was based on self-reported use, and this was administered at the hospital. Logistic regression was used to estimate predictors of hospitalization due to COVID-19. There were 278 pregnant women included in the study, of which 41 (14.7%) required hospitalization due to COVID-19. The remaining 237 (85.3%) had mild symptoms or were asymptomatic. Most of the women had the infection in the third trimester ( = 149; 53.6%). The most prevalent medications used across all trimesters were analgesics (2.4% to 20.0%), antibacterials (15.0% to 23.1%), and corticosteroids (7.2% to 10.4%). Pre- or gestational hypertensive disorder (odds ratio (OR) 4.94, 95% confidence interval (CI) 1.65, 14.87) and having at least one dose of vaccine against SARS-CoV-2 (OR 0.13, 95% CI 0.04, 0.39) were associated with hospitalization due to COVID-19. Analgesics, antibacterials, and corticosteroids were the most frequently used medications among pregnant women with COVID-19. Women with hypertensive disorders have almost a five-fold increased risk of hospitalization due to COVID-19. Vaccination was the strongest protective factor for severe COVID-19. The COVID-19 vaccination among pregnant women should be promoted, and pregnant women diagnosed with COVID-19 who have hypertensive disorders should be closely monitored.
关于 COVID-19 孕妇用药以及 COVID-19 住院风险因素的证据有限。我们旨在描述巴西两家医院感染前后 SARS-CoV-2 阳性孕妇的用药情况，并确定 COVID-19 住院的预测因素。这是一项基于医院记录的研究，纳入了 2020 年 3 月至 2022 年 8 月期间巴西两家医院 SARS-CoV-2 检测呈阳性的孕妇。回顾性提取社会人口统计学、产科和 COVID-19 症状特征。药物的普遍使用是基于自我报告的使用情况，并在医院进行管理。使用逻辑回归估计 COVID-19 住院的预测因素。研究共纳入 278 名孕妇，其中 41 名（14.7%）因 COVID-19 需要住院。其余 237 名（85.3%）症状轻微或无症状。大多数女性在妊娠晚期感染（=149；53.6%）。所有孕期最常见的药物是镇痛药（2.4%20.0%）、抗菌药（15.0%23.1%）和皮质类固醇（7.2%10.4%）。妊娠前或妊娠高血压疾病（比值比（OR）4.94，95%置信区间（CI）1.6514.87）和至少接种过一次 SARS-CoV-2 疫苗（OR 0.13，95%CI 0.04~0.39）与 COVID-19 住院有关。COVID-19 孕妇中最常使用的药物是镇痛药、抗菌药和皮质类固醇。患有高血压疾病的女性 COVID-19 住院风险几乎增加了五倍。疫苗接种是 COVID-19 严重程度的最强保护因素。应促进 COVID-19 孕妇接种疫苗，密切监测患有 COVID-19 的高血压孕妇。
